Wolfgang Holzer

Title: Wolfgang Holzer: Innovator in Targeted Tumor Therapy

Introduction

Wolfgang Holzer is a notable inventor based in Darmstadt, Germany. He has made significant contributions to the field of immunology, particularly in the development of targeted therapies for cancer treatment. His innovative work has led to the creation of a patent that holds promise for improving patient outcomes in tumor therapy.

Latest Patents

Wolfgang Holzer holds a patent for "Immunoconjugates II." This invention provides new immunoconjugates that comprise a monoclonal antibody or a fragment thereof, which is specific for the human EGF-receptor molecule. The immunoconjugates also include a member of the chemokine family, preferably selected from the C-X-C family, such as Interleukin-8 (IL-8). These immunoconjugates are designed to induce cytotoxic and chemotactic activity, making them suitable for targeted tumor therapy. He has 1 patent to his name.

Career Highlights

Throughout his career, Wolfgang Holzer has worked with prominent companies in the pharmaceutical and biotechnology sectors. Notably, he has been associated with Merck Patent Gesellschaft mit beschränkter Haftung and Dk-Spec Inc. His experience in these organizations has allowed him to refine his expertise in immunology and therapeutic development.

Collaborations

Wolfgang Holzer has collaborated with several professionals in his field, including Ilka Von Hoegen and Wolfgang Strittmatter. These collaborations have contributed to the advancement of his research and the successful development of his patented technologies.

Conclusion

Wolfgang Holzer's innovative work in the field of immunoconjugates represents a significant advancement in targeted tumor therapy. His contributions continue to influence the landscape of cancer treatment, showcasing the importance of innovation in medical science.